汤臣倍健 reported revenue of ¥3.67B for the period ended 2026-06-30, +3.9% year on year. Net income was ¥0.61B, a 16.6% net margin on a 70.3% gross margin. The largest revenue line is 胶囊 at 40% of the total. Free cash flow for the period was ¥0.09B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥3.67B | +3.9% |
| Gross profit | ¥2.58B | — |
| Operating income | ¥0.77B | — |
| Net income | ¥0.61B | -20.0% |
| Gross margin | 70.3% | Net margin 16.6% |
| Revenue Q/Q | -3.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 胶囊 | ¥1.47B | 40.1% |
| 片剂 | ¥1.07B | 29.2% |
| 粉剂 | ¥0.97B | 26.4% |
| 其他 | ¥0.16B | 4.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.09B | 29.7% |
| R&D | ¥0.05B | 1.4% |
| SG&A | ¥1.76B | 48.0% |
| Tax & other | ¥0.16B | 4.4% |
| Item | Amount |
|---|---|
| Total assets | ¥13.44B |
| Total liabilities | ¥2.50B |
| Shareholders' equity | ¥10.94B |
| Equity / assets | 81.4% |
| Operating cash flow | ¥0.13B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥0.09B |
| Cash conversion (OCF / net income) | 29% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
*ST香雪 ・ 天舟文化 ・ 睿智医药 ・ 世纪瑞尔 ・ 昌红科技 ・ *ST动力 ・ 科泰电源 ・ 瑞凌股份 ・ 安居宝 ・ 新锦动力 ・ 振东制药 ・ 新研股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies